MedPath

Implementation and Outcome of Minimally Invasive Pancreatoduodenectomy in Europe:

Completed
Conditions
Pancreas Disease
Registration Number
NCT06135233
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Detailed Description

The European registry for Minimally Invasive Pancreatic Surgery (E-MIPS) is an E-AHPBA endorsed registry with the aim to monitor and safeguard the introduction of MIPD in Europe. International multicenter audit-based studies focusing on outcomes of minimally invasive pancreatoduodenectomy (MIPD) are lacking.

A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1336
Inclusion Criteria
  • Data from all patients who underwent R-MIPD and L-MIPD between January 1st 2019 and December 31st 2021 were included
Exclusion Criteria
  • Other pancreatic procedures
  • Hybrid approaches (reconstruction phase open)
  • Procedures with insufficient baseline data / missing primary outcome data.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
30-day/in-hospital mortality.30 days
Major morbidity30 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Amsterdam UMC, locatie AMC

🇳🇱

Amsterdam, Noord-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath